Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis
Authors:
- Lee D. CranmerLCLee D. Cranmer
- Bonny ChauBCBonny Chau
- Jose G. MantillaJMJose G. Mantilla
- Elizabeth T. LoggersELElizabeth T. Loggers
- Seth M. PollackSPSeth M. Pollack
- Teresa S. KimTKTeresa S. Kim
- Edward Y. KimEKEdward Y. Kim
- Gabrielle M. MB KaneGKGabrielle M. MB Kane
- Matthew J. ThompsonMTMatthew J. Thompson
- Jared L. Md HarwoodJHJared L. Md Harwood
- Michael J. WagnerMWMichael J. Wagner
- 14 October 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 480 (4) , 748-758
Abstract
Background: Dedifferentiated chondrosarcoma is a chondrosarcoma subtype associated with high rates of recurrence and a poor prognosis. Others have proposed treatment of dedifferentiated chondrosarcoma using osteosarcoma protocols, including perioperative chemotherapy. However, the rarity of this condition poses difficulties in undertaking single- institution studies of sufficient sample size. Question/purpose: Is perioperative chemotherapy associated with improved overall survival in patients with dedifferentiated chondrosarcoma? Methods: We queried the Surveillance, Epidemiology, and End Results (SEER) 1973 to 2016 database for patients with a diagnosis of dedifferentiated chondrosarcoma (n = 308). As dedifferentiated chondrosarcoma was only classified as a distinct entity in SEER starting in 2000, only patients treated in 2000 and later were included. We excluded from our analyses those patients with distant disease at diagnosis, a primary site of disease other than bone or joints, and those who did not receive cancer-directed surgery. These criteria yielded 185 dedifferentiated chondrosarcoma patients for inclusion. We used Kaplan-Meier analyses and Cox proportional hazards models to assess the association of clinical, demographic, and treatment characteristics on overall survival (OS). Results: After controlling for confounding variables, including age, sex, tumor size, stage, grade, location, and radiation treatment status, and after adjusting for missing data, no overall survival benefit was associated with receipt of chemotherapy in patients with dedifferentiated chondrosarcoma (hazard ratio 0.75 [95% confidence interval 0.49 to 1.12]; p = 0.16). Conclusion: Chemotherapy treatment of dedifferentiated chondrosarcoma was not associated with improved OS. These results must be viewed cautiously, given the limited granularity of information on chemotherapy treatment, the concerns regarding chemotherapy misclassification in SEER data, and the small sample of patients with dedifferentiated chondrosarcoma, all of which limit the power to detect a difference. Our findings are nevertheless consistent with those of prior reports in which no benefit of chemotherapy could be detected. Lack of clear benefit from perioperative chemotherapy in dedifferentiated chondrosarcoma argues that it should be used only after careful consideration, and ideally in the context of a clinical trial. Level of Evidence: Level III, therapeutic study.Keywords
This publication has 41 references indexed in Scilit:
- Survival and prognostic factors in chondrosarcomaActa Orthopaedica, 2011
- A Systematic Review and Meta-analysis of Intralesional Versus Wide Resection for Intramedullary Grade I Chondrosarcoma of the ExtremitiesAnnals of Surgical Oncology, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimicsLaboratory Investigation, 2010
- A systematic review of proton therapy in the treatment of chondrosarcoma of the skull baseNeurosurgical Review, 2009
- Imputing missing covariate values for the Cox modelStatistics in Medicine, 2009
- Pediatric sarcomas occurring in adultsJournal of Surgical Oncology, 2008
- Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European groupEuropean Journal of Cancer, 2007
- Dedifferentiated central chondrosarcomaCancer, 2006
- Cryosurgery in aggressive, benign, and low-grade malignant bone tumoursThe Lancet Oncology, 2005